User:Mr. Ibrahem/Lapatinib

Mr. Ibrahem/Lapatinib
Clinical data
Trade names	Tykerb, Tyverb, others
Other names	Lapatinib ditosylate
AHFS/Drugs.com	Monograph
MedlinePlus	a607055
License data	EU EMA: by INN; US DailyMed: Lapatinib; US FDA: Lapatinib;
Pregnancy; category	AU: C; ;
Routes of; administration	By mouth (tablets)
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; UK: POM (Prescription only); US: ℞-only; In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	Variable, increased with food
Protein binding	>99%
Metabolism	Liver, mostly CYP3A-mediated (minor 2C19 and 2C8 involvement)
Elimination half-life	24 hours (repeated dosing), 14.2 hours (single dose)
Excretion	Mostly Feces
Identifiers
	IUPAC name N-[3-Chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-; [5-[(2-methylsulfonylethylamino)methyl]-2-furyl]; quinazolin-4-amine;
Chemical and physical data
Formula	C29H26ClFN4O4S
Molar mass	581.06 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CS(=O)(=O)CCNCc1ccc(o1)c2ccc3c(c2)c(ncn3)Nc4ccc(c(c4)Cl)OCc5cccc(c5)F;
	InChI InChI=1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35) ; Key:BCFGMOOMADDAQU-UHFFFAOYSA-N ;
	(what is this?) (verify)

Lapatinib, sold under the brand names Tykerb and Tyverb is a medication used to treat breast cancer.^[1] Specifically it is used for HER2 positive breast cancer with either letrozole, trastuzumab, or capecitabine.^[1]^[2] It is taken by mouth.^[1]

Common side effects include diarrhea, nausea, rash, tiredness, liver problems, itchiness, and hair loss.^[1] Other side effects may include QT prolongation, pneumonitis, low platelets, low red blood cells, or low white blood cells.^[1] Use in pregnancy may harm the baby.^[1] It is a tyrosine kinase inhibitor which blocks HER2/neu and epidermal growth factor receptor (EGFR).^[3]

Lapatinib was approved for medical use in the United States in 2007 and Europe in 2008.^[1]^[2] In the United Kingdom 4 weeks of 1,000 mg costs the NHS about £970 as of 2021.^[4] This amount in the United States costs about 4,300 USD.^[5]

References[edit]

^ ^a ^b ^c ^d ^e ^f ^g "Lapatinib Monograph for Professionals". Drugs.com. Archived from the original on 26 January 2021. Retrieved 20 November 2021.
^ ^a ^b "Tyverb". Archived from the original on 23 October 2021. Retrieved 20 November 2021.
^ Higa GM, Abraham J (September 2007). "Lapatinib in the treatment of breast cancer". Expert Review of Anticancer Therapy. 7 (9): 1183–92. doi:10.1586/14737140.7.9.1183. PMID 17892419. S2CID 36837880. Archived from the original on 2021-05-25. Retrieved 2021-10-03.
^ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1031. ISBN 978-0857114105.
^ "Lapatinib Prices, Coupons & Patient Assistance Programs". Drugs.com. Retrieved 20 November 2021.

[AHFS2021-1] ^ ^a ^b ^c ^d ^e ^f ^g "Lapatinib Monograph for Professionals". Drugs.com. Archived from the original on 26 January 2021. Retrieved 20 November 2021.

[EPAR2021-2] "Tyverb". Archived from the original on 23 October 2021. Retrieved 20 November 2021.

[Higa2007-3] Higa GM, Abraham J (September 2007). "Lapatinib in the treatment of breast cancer". Expert Review of Anticancer Therapy. 7 (9): 1183–92. doi:10.1586/14737140.7.9.1183. PMID 17892419. S2CID 36837880. Archived from the original on 2021-05-25. Retrieved 2021-10-03.

[BNF81-4] BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1031. ISBN 978-0857114105.

[5] "Lapatinib Prices, Coupons & Patient Assistance Programs". Drugs.com. Retrieved 20 November 2021.

[1]

[2]

[3]

[4]

[5]